JP2010540654A - ゲルからのコンプスタチンアナログの持続的送達 - Google Patents

ゲルからのコンプスタチンアナログの持続的送達 Download PDF

Info

Publication number
JP2010540654A
JP2010540654A JP2010528129A JP2010528129A JP2010540654A JP 2010540654 A JP2010540654 A JP 2010540654A JP 2010528129 A JP2010528129 A JP 2010528129A JP 2010528129 A JP2010528129 A JP 2010528129A JP 2010540654 A JP2010540654 A JP 2010540654A
Authority
JP
Japan
Prior art keywords
compstatin analog
liquid composition
compstatin
composition
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010528129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540654A5 (https=
Inventor
セドリック フランソワ，
パスカル デスシャテレツ，
ポール オルソン，
Original Assignee
ポテンシア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポテンシア ファーマシューティカルズ， インコーポレイテッド filed Critical ポテンシア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2010540654A publication Critical patent/JP2010540654A/ja
Publication of JP2010540654A5 publication Critical patent/JP2010540654A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010528129A 2007-10-02 2008-10-02 ゲルからのコンプスタチンアナログの持続的送達 Pending JP2010540654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US2646008P 2008-02-05 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Publications (2)

Publication Number Publication Date
JP2010540654A true JP2010540654A (ja) 2010-12-24
JP2010540654A5 JP2010540654A5 (https=) 2011-10-27

Family

ID=40526950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528129A Pending JP2010540654A (ja) 2007-10-02 2008-10-02 ゲルからのコンプスタチンアナログの持続的送達

Country Status (12)

Country Link
US (1) US20110182877A1 (https=)
EP (1) EP2207530A4 (https=)
JP (1) JP2010540654A (https=)
KR (2) KR20150080007A (https=)
CN (1) CN101854916A (https=)
AU (1) AU2008308657A1 (https=)
BR (1) BRPI0817524A2 (https=)
CA (1) CA2701470A1 (https=)
MX (1) MX2010003630A (https=)
RU (1) RU2505311C2 (https=)
WO (1) WO2009046198A2 (https=)
ZA (1) ZA201002365B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523882A (ja) * 2011-06-22 2014-09-18 アペリス・ファーマシューティカルズ・インコーポレイテッド 補体阻害剤による慢性障害の治療方法
JP2024028797A (ja) * 2017-12-15 2024-03-05 アペリス・ファーマシューティカルズ・インコーポレイテッド 投与レジメンならびに関連組成物および方法
US12528836B2 (en) 2015-10-07 2026-01-20 Apellis Pharmaceuticals, Inc. Dosing regimens

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
ES2426603T3 (es) 2010-09-03 2013-10-24 Novagali Pharma S.A. Una emulsión de tipo agua en aceite para tratar una enfermedad de los ojos
GEP201706606B (en) 2010-09-03 2017-01-25 Santen Sas Water-in-oil type emulsion for treating a disease of the eye
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
CN103687867B (zh) 2011-05-11 2017-02-08 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
CA2970502A1 (en) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
CN113966224A (zh) 2019-06-04 2022-01-21 Ra制药公司 采用补体抑制剂的炎性疾病治疗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044668A2 (en) * 2005-10-08 2007-04-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
PT1549333E (pt) * 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2390828T3 (es) * 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
CN101346473A (zh) * 2005-12-22 2009-01-14 爱尔康研究有限公司 用于在具有补体因子h的风险变体的患者中预防和治疗年龄相关性黄斑变性的c3-转化酶抑制剂
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
PL2148691T3 (pl) * 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044668A2 (en) * 2005-10-08 2007-04-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523882A (ja) * 2011-06-22 2014-09-18 アペリス・ファーマシューティカルズ・インコーポレイテッド 補体阻害剤による慢性障害の治療方法
US10039802B2 (en) 2011-06-22 2018-08-07 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
JP2018138603A (ja) * 2011-06-22 2018-09-06 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体阻害剤による慢性障害の治療方法
JP2020045361A (ja) * 2011-06-22 2020-03-26 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 補体阻害剤による慢性障害の治療方法
US11013782B2 (en) 2011-06-22 2021-05-25 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US11712460B2 (en) 2011-06-22 2023-08-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US12528836B2 (en) 2015-10-07 2026-01-20 Apellis Pharmaceuticals, Inc. Dosing regimens
JP2024028797A (ja) * 2017-12-15 2024-03-05 アペリス・ファーマシューティカルズ・インコーポレイテッド 投与レジメンならびに関連組成物および方法
US12290566B2 (en) 2017-12-15 2025-05-06 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US12458695B2 (en) 2017-12-15 2025-11-04 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods

Also Published As

Publication number Publication date
RU2505311C2 (ru) 2014-01-27
KR20150080007A (ko) 2015-07-08
EP2207530A4 (en) 2013-09-11
US20110182877A1 (en) 2011-07-28
ZA201002365B (en) 2010-12-29
BRPI0817524A2 (pt) 2017-05-02
AU2008308657A1 (en) 2009-04-09
CA2701470A1 (en) 2009-04-09
MX2010003630A (es) 2010-04-21
WO2009046198A2 (en) 2009-04-09
WO2009046198A3 (en) 2009-07-16
CN101854916A (zh) 2010-10-06
KR20100094453A (ko) 2010-08-26
EP2207530A2 (en) 2010-07-21
RU2010113513A (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
RU2505311C2 (ru) Пролонгированная доставка аналогов компстатина из гелей
JP6305382B2 (ja) 眼の障害のためのコンプスタチンおよびそのアナログ
US10407466B2 (en) Methods of selecting compstatin mimetics
US8580735B2 (en) Local complement inhibition for treatment of complement-mediated disorders
AU2006223108A1 (en) Compositions comprising modulators of G-protein-coupled receptor for treatment of macular degeneration
AU2016253654A1 (en) Injectable combination therapy for eye disorders
HK1121380A (en) Compstatin and analogs thereof for eye disorders
HK1121380B (en) Compstatin and analogs thereof for eye disorders
MX2008004656A (es) Compstatina y analogos de la misma para tratar trastornos oculares

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110908

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130729

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130902

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140603